【Objective】The pharmacokinetical characteristics and bioavailability of pleuromutilin derivative BC-7013 in chickens were investigated. 【Method】 Twenty chickens were randomly divided into two groups for pharmacokinelical experiments after a single intravenous (2.5 mg·kg-1) and oral administration (15 mg·kg-1). Blood samples were collected at different intervals after the administration of derivative BC-7013. The concentrations of derivative BC-7013 in plasma were determined by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) with internal standard method. Plasma concentration-time profiles of derivative BC-7013 were analyzed by using non-compartmental analysis WinNonlin 5.2 software. 【Result and conclusion】 The main pharmacokinetical parameters of i.v. administration were as follows：t_1/2β =（1.37±0.14） h，Vd=（1.87±0.25） L·kg^-1，AUC_(0→∞) =（2.83±0.56） μg·mL^-1·h，CL=（1.14±0.28） L·h^-1·kg^-1. The major pharmacokinetical parameters of oral administration were as follows：t_max =（1.94±0.26） h，C_max =（126.18±6.54） ng·mL^-1，AUC_(0→∞) =（1.38±0.21） μg·mL^-1·h，MRT=（9.49±0.57） h，F =（10.37±1.48）%. The results show that the pharmacokinetical characteristics of pleuromutilin derivative BC-7013 in healthy chicken manifest wide distribution， rapid elimination as well as incomplete absorption and low oral bioavailability.